Beck Miller, M.P.H

DIRECTOR, PHARMACEUTICAL COMMERCIALIZATION

CONTACT INFORMATION

BlueRidge Life Sciences
Pharmaceutical Commercialization
Decatur, GA 30030
Phone (404) 850-6091 (office)
Phone (508) 330-0419 (mobile)
bmiller@blueridgelifesciences.com

PROFESSIONAL PROFILE

Mr. Beck Miller is Director of the BlueRidge Life Sciences Pharmaceutical Commercialization practice. He is a strategic health economics and outcomes research (HEOR) leader with extensive experience developing and managing cost-effectiveness, budget impact, and cost-consequence models to support global market access. With a proven track record leading cross-functional projects supporting engagement with HTA bodies (NICE, ICER, BeneLuxa, Nordics), Mr. Miller delivers evidence-based insights that strategically inform commercial decisions and evidence-generation activities. He is adept at client engagement and translating complex analyses into succinct, actionable strategies for diverse stakeholders.

In his previous roles as an associate director and research scientist, Mr. Miller has significant experience developing and programming advanced HEOR models, including model design, client engagement, and strategic support during ICER reviews and HTA submissions. He is able to both independently and collaboratively develop health economic models using Excel and VBA for submissions. Other expertise includes managing cost-effectiveness, cost-consequence, and budget impact models to ensure methodological rigor and alignment with HTA and payer requirements, and utilizing R to conduct model analyses.

As a leader in his field, Mr. Miller has served as a HEOR representative in cross-functional initiatives, integrating modeling insights into broader strategy. He has directed and supervised HEOR modeling projects with multiple team members, helping to foster collaboration and skills development, while simultaneously establishing strategic client partnerships and presenting model frameworks tailored for decision making across diverse stakeholders. He has disseminated his work through publications in peer-reviewed journals and presentations at a variety of scientific conferences.

EDUCATION AND DEGREES EARNED

2018 Master of Public Health, (M.P.H.), Public Health and Epidemiology
Rollins School of Public Health
Emory University, Atlanta, GA

2016 Bachelor of Science (B.S.), Biological Science with Mathematics minor, *cum laude*
Marist College, Poughkeepsie, NY

SELECTED PROFESSIONAL EXPERIENCE

Value Demonstration and Economic Modeling

Oversaw service line engagements for clients in pharmaceutical, biotechnology, medical device, and diagnostic companies.

Conceptualized and implemented models to communicate evidence-based value of client assets to payers and providers in the US and Europe.

Provided review and quality of control of proposals, reports, dossiers, and health economic models.

Managed a multi-year client partnership to develop a de-novo cost effectiveness model for a gene therapy for Metachromatic Leukodystrophy (MLD). This model was used by the client with multiple HTA submissions in Europe and guidance for their ICER review in the United States, and was instrumental in justifying launch pricing for their one-time treatment.

Developed a de-novo cost-effectiveness and budget impact analysis of a gene therapy for Spinal Muscular Atrophy Type 1 (SMA1). This multi-year engagement included developing a client's early CEA and optimizing and adapting it for HTA submissions across Europe, Japan, and South America, as well as alternative indications.

Developed and managed web-based surveys of parents and caregivers of children with XLMTM in collaboration with clients, clinicians, and patient advocates to directly gather information on the burden of illness. The success of the survey in the United States led to developing peer-reviewed publications and further surveys conducted in the UK, Germany, and Spain, with follow-on publications.

MANUSCRIPTS AND PUBLISHED ABSTRACTS

Haselkorn T, Lennox A, Schara-Schmidt U, Hughes W, Roca A, **Miller B**, Jensen I, et al. A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United Kingdom, Germany, and Spain. [*In review]*

Duong T, Haselkorn T, **Miller B**, Coats J, Jensen I, Ward E, Wood M, Graham RJ, Servais L. 2025. A real-world analysis of the impact of x-linked myotubular myopathy on caregivers in the United States. Orphanet J Rare Dis 20(1):224; doi: 10.1186/s13023-025-03583-w.

Sidhu MK, **Miller B**, Jensen I, Rabiner P. 2025. Abstract EE171: Conceptual framework for a de novo cost-effectiveness model in glycogen storage disease type Ia (GSDIa). Value in Health 28(6-Sup1):S93-S94; doi: 10.1016/j.jval.2025.04.463.

Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, Chanson C, Olaye A, **Miller B**, et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045.

Haselkorn T, Hughes W, Schara-Schmidt U, Lennox A, Roca A, **Miller B**, Jensen I, Solomon F, et al. 2024. Abstract PCR257: Real-world impact of x-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Value in Health 27(12-Sup):S557; doi: 10.1016/j.val.2024.10.3499.

Majhail NS, **Miller B**, Dean R, Manghani R, Shin H, Sivaraman S, Maziarz RT. 2023. Hospitalization and healthcare resource utilization of omidubicel-only versus umbilical cord blood transplantation for hematologic malignancies: Secondary analysis from a pivotal phase 3 clinical trial. Transplant Cell Ther 29(12):749.e1-749.e5; doi: 10.1016/j.jtct.2023.09.004.

Pang F, Dean R, Jensen I, Bean K, Fields C, **Miller B**. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, Bean K, **Miller B**. 2022. Abstract EE24: The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Value in Health 25(7-Supp):S339; doi: 10.1016/j.jval.2022.04.276.

Dean R, Jensen I, Cyr P, **Miller B**, Maru B, Sproule DM, Feltner DE, Wiesner T., et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841.

Majhail NS, **Miller B**, Dean R, Manghani R, Sivaraman S, Galamidi-Cohen E, Maziarz RT. 2021. Hospitalization and healthcare resource use of omidubicel vs cord blood transplantation for hematological malignancies in a global randomized phase III clinical trial. Blood 138(Sup 1):4036; doi: 10.1182/blood-2021-147480.

Dean R, **Miller B**, Arjunji R, Awano H, Igarashi A, Tanaka S, Feltner DE, Sproule DM, et al. 2020. Abstract PMU36: Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment in Japan. Value in Health 23(Sup 1):S239; doi: 10.1016/j.val.2020.04.810.

Miller B, Jensen I, Dean R, Slocomb T, James ES, Beggs AH. 2020. Abstract PRO77: Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS study. Value in Health 23(Sup 1):S342; doi: 10.1016/j.jval.2020.04.1298.

Miller B, Yao W, Dean R, Jensen IS, Cyr PL, Slocomb T. 2020. Abstract PMS57: Understanding the impact of XLMTM on parents and caregivers in the US: An analysis of survey results. Value in Health 23(Sup 2):S601; doi: 10.1016/j.jval.2020.08.1188.

Arjunji R, Dean R, Jensen IS, **Miller B**, Menier M, Sproule DM, Feltner DE, Droege M, et al. 2019. Abstract PBI10: Type I spinal muscular atrophy patients treated with AVXS-101 have lower use of ventilatory support, hospitalization, and associated costs compared to those treated with nusinersen. Value in Health 22(Sup 2):S48; doi: 10.1016/j.jval.2019.04.093.

Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, **Miller B**, Maru B, Sproule DM, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):16011484; doi: 10.1080/20016689.2019.1601484.

Malone DC, Dean R, **Miller B**, Arjunji R, Feltner DE, Sproule D, Jensen IS, Maru B, Dabbous O. 2019. Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment. Value in Health 22(Sup 2):S42-S43; doi: 10.1016/j.jval.2019.04.060.

Malone D, **Miller B**, Dean R, Arjunji R, Jensen IS, Maru B, Dabbous O. 2019. Abstract PRO10: Use of single dose gene-replacement therapy for the treatment of spinal muscular atrophy type 1: A United States payer budget impact analysis. Value in Health 22(Sup2):S336-S337; doi: 10.1016/j.jval.2019.04.1644.

PRESENTATIONS

Nordyke RJ, Jensen I, Hooda N, **Miller B**. Rising levels of innovation in expedited designations among FDA-approved drugs: 2012-2024. Poster Session 2/No. HPR63, ISPOR 2026, Philadelphia, PA, May 18, 2026.

Sidhu M, **Miller B**, Jensen I, Rabiner P. Conceptual framework for a de-novo cost-effectiveness model framework in glycogen storage disease type Ia (GSDIa). ISPOR 2025, Montreal, May 2025.

Haselkorn T, Hughes W, Lennox A, Schara-Schmidt U, Roca A, **Miller B**, Jensen I, et al. Real-world impact of Xlinked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. ISPOR Europe 2024, November 2024 (*Top 5% Finalist*).

Haselkorn T, Roca A, **Miller B**, Jensen I, Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, November 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, **Miller B**. The cost-effectiveness of atidarsagene autotemcel (ARSACEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain. ISPOR Europe 2024, November 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, **Miller B**. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a Part of the Beneluxa Initiative for ISPOR Europe 2024, November 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, **Miller B**. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. ISPOR Europe 2023.

Bean K, Olaye A, **Miller B**, Jensen I, Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. ISPOR 2023.

Bean K, **Miller B**, Jensen I, Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). ISPOR 2023.

Bean K, **Miller B**, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. ISPOR Europe 2023.

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. ISPOR Europe 2023.

Pang F, Dean R, Jensen I, Bean K, Fields C, **Miller B**. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the United States. WorldSymposium, Orlando, FL, February 2023.

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, Bean K, **Miller B**. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. ISPOR 2022.

Pang F, Dean R, Jensen I, Olaye A, **Miller B**. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD). ISPOR 2021.

Miller B, Jensen IS, Dean R, Cyr PL, Slocomb T, James E, et al. Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS Study. ISPOR 25th Annual International Meeting, Orlando, FL, 2020.

Dean R, Arjunji R, Awano H, Igarash A, Tanaka A, Jensen IS, **Miller B** et al. Cost effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan. ISPOR 25th Annual International Meeting, Orlando, FL, 2020.

Dean R, **Miller B**, Arjunji R, Feltner DE, Sproule DM, Jensen I, Dabbous O. Cost-utility analysis of single dose gene replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment in Japan. ISPOR 2020.

Miller B, Jensen IS, Dean R, Cyr PL, Slocomb T, James E, Beggs AH. Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS study. ISPOR 2020.

Malone D, **Miller B**, Dean R, Arjunji R, Jensen IS, Maru B, et al. Use of single dose gene-replacement therapy for the treatment of spinal muscular atrophy type 1: A United States payer budget impact analysis. ISPOR 2019.

Miller B. Study of the immunological response to diacetylmorphine and methadone using avian model. Presentation at American Association for the Advancement of Science, Washington, DC, February 2016.

Miller B. Analysis of the fetal immunological response to diacetylmorphine and methadone using avian models. Presentation at Eastern Colleges Science Conference, Niagara University, Niagara, NY, April 2016. (*Received Excellence Awards for Manuscript of Research and Oral Presentation of Research*)

Miller B. Effects of rhodium exposure on human lymphocytes (*in vitro*). Presentation at Society of Environmental Toxicology and Chemistry (SETAC), Vancouver, Canada, November 2014.